Susan G. Komen® unveils $26 million investment in research, focused on metastatic breast cancer and new treatments

Susan G. Komen®, the world’s leading breast cancer organization, today announced $26 million in funding for new research projects that focus on metastatic breast cancer, developing new, more-effective treatments, and addressing disparities in breast cancer outcomes. This year’s grant slate focuses on key areas that will help the organization achieve its Bold Goal to reduce the current number of breast cancer deaths in the U.S. by 50 percent by 2026.

 

Click here to read more.